F-star Therapeutics, Inc. Common Stock
FSTX
FSTX was delisted on the 8th of March, 2023.
33 hedge funds and large institutions have $48.7M invested in F-star Therapeutics, Inc. Common Stock in 2017 Q2 according to their latest regulatory filings, with 19 funds opening new positions, 10 increasing their positions, 1 reducing their positions, and 4 closing their positions.
900% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 1
375% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 4
364% more capital invested
Capital invested by funds: $10.5M → $48.7M (+$38.3M)
83% more funds holding
Funds holding: 18 → 33 (+15)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
+$7.13M |
| 2 |
RI
RTW Investments
New York
|
+$2.89M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
+$2.84M |
| 4 |
Axa
Paris,
France
|
+$2.47M |
| 5 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
+$2.03M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Charles Schwab
San Francisco,
California
|
-$252K |
| 2 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$239K |
| 3 |
Goldman Sachs
New York
|
-$180K |
| 4 |
Millennium Management
New York
|
-$174K |
| 5 |
Bessemer Group
Woodbridge,
New Jersey
|
-$11K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
DCM
26
DAFNA Capital Management
Los Angeles,
California
| $217K | +$18.5K | +400 | New |
|
|
WSFS
27
Wilmington Savings Fund Society
Wilmington,
Delaware
| $190K | – | – | – |
|
28
Morgan Stanley
New York
| $98K | +$11.6K | +250 | +16% |
|
|
SQA
29
Simon Quick Advisors
Morristown,
New Jersey
| $88K | +$75.3K | +1,625 | New |
|
30
UBS Group
Zurich,
Switzerland
| $34K | +$2.13K | +46 | +8% |
|
|
EWM
31
Evercore Wealth Management
New York
| $14K | +$11.6K | +250 | New |
|
|
LTFS
32
Ladenburg Thalmann Financial Services
Miami,
Florida
| $7K | +$5.79K | +125 | New |
|
33
Royal Bank of Canada
Toronto,
Ontario, Canada
| $2K | +$2.08K | +45 | New |
|
|
34
Luther King Capital Management (LKCM)
Fort Worth,
Texas
| – | -$239K | -7,795 | Closed |
|
|
35
Charles Schwab
San Francisco,
California
| – | -$252K | -7,075 | Closed |
|
|
36
Goldman Sachs
New York
| – | -$180K | -5,062 | Closed |
|
|
37
Bessemer Group
Woodbridge,
New Jersey
| – | -$11K | -313 | Closed |
|
FSTX Hedge Fund Activity: Q2 2017 in Review
33 of the 4,012 institutional investors tracked by Wall St. Rank reported a position in F-star Therapeutics, Inc. Common Stock (FSTX) for Q2 2017, worth a combined $48.7M — up 364% from $10.5M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new FSTX positions and 4 closed out — a net gain of 15 holders — while 10 added to existing stakes and 1 trimmed.
The largest buyer was BVF Inc, opening a new position worth an estimated $7.13M. The largest seller was Charles Schwab, exiting entirely with an estimated $252K sold.
- 33 institutional investors held F-star Therapeutics, Inc. Common Stock (FSTX) as of Q2 2017, up from 18 in Q1 2017.
- Funds reported $48.7M of F-star Therapeutics, Inc. Common Stock stock for Q2 2017, up 364% quarter-over-quarter.
- 19 funds opened new F-star Therapeutics, Inc. Common Stock positions in Q2 2017 and 4 closed out, a net change of +15 holders.
- The largest F-star Therapeutics, Inc. Common Stock buyer in Q2 2017 was BVF Inc, an estimated $7.13M added.
- The largest F-star Therapeutics, Inc. Common Stock seller in Q2 2017 was Charles Schwab, an estimated $252K sold.
Based on aggregated 13F filings for Q2 2017.